Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants-Reference-Cited by-同舟云学术

Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants

Published:2022-06-29 Issue:3 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Chaki Sankar Prasad¹^ORCID,Kahl-McDonagh Melissa M.¹,Neuman Benjamin W.¹²,Zuelke Kurt A.¹

Affiliation:

1. Texas A&M Global Health Research Complex, Division of Research, Texas A&M University, College Station, Texas, USA

2. Department of Biology, College of Science, Texas A&M University, College Station, Texas, USA

Abstract

The coronavirus disease 2019 (COVID-19) pandemic resulted in 427 million infections and 5.9 million deaths globally as of 21 February 2022. SARS-CoV-2, the causative agent of the COVID-19 pandemic, frequently mutates and has developed into variants of major public health concerns.

Funder

U.S. Department of Education

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.00665-22

Reference39 articles.

1. WHO. 2022. WHO coronavirus (COVID-19) dashboard. WHO Geneva Switzerland. https://covid19.who.int/.

2. WHO. 2022. World Health Organization tracking SARS-CoV-2 variants. WHO Geneva Switzerland. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.

3. CDC. 2022. SARS-CoV-2 variant classifications and definitions. CDC Atlanta GA. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html.

4. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose

5. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease;2023-09-29

2. Montelukast and Telmisartan as Inhibitors of SARS-CoV-2 Omicron Variant;Pharmaceutics;2023-07-05

3. An Azapeptide Platform in Conjunction with Covalent Warheads to Uncover High-Potency Inhibitors for SARS-CoV-2 Main Protease;2023-04-12

4. CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern;TrAC Trends in Analytical Chemistry;2023-04

5. Clinical performance of rapid antigen tests in comparison to RT‐PCR for SARS‐COV‐2 diagnosis in Omicron variant: A systematic review and meta‐analysis;Reviews in Medical Virology;2023-02-15